Mouse Monoclonal PRKAG1 Antibody

The PRKAG1 antibody targets the gamma-1 subunit of the AMP-activated protein kinase (AMPK), a critical energy sensor in eukaryotic cells. AMPK is a heterotrimeric enzyme composed of α, β, and γ subunits, with PRKAG1 (γ1) being one of three γ isoforms (γ1. γ2. γ3). The γ subunit plays a central role in energy homeostasis by binding adenosine nucleotides (AMP, ADP, ATP), allowing AMPK to detect cellular energy status. When activated by low energy (high AMP/ADP), AMPK phosphorylates downstream targets to restore balance by promoting catabolic processes (e.g., glucose uptake, fatty acid oxidation) and inhibiting anabolic pathways. PRKAG1 is ubiquitously expressed and implicated in metabolic regulation, with genetic variants linked to cardiac arrhythmias, hypertrophic cardiomyopathy, and metabolic syndromes. Antibodies against PRKAG1 are essential tools for studying AMPK’s structure, function, and tissue-specific expression. They enable detection of PRKAG1 in techniques like Western blotting, immunofluorescence, and immunohistochemistry, aiding research on metabolic diseases, cancer, and cardiovascular disorders. Additionally, these antibodies help elucidate mechanisms underlying AMPK-related pathologies, such as insulin resistance or abnormal lipid metabolism, by visualizing γ1 subunit localization and expression changes under stress or disease conditions. Validated PRKAG1 antibodies are crucial for ensuring specificity in experimental models, supporting both basic research and therapeutic development.